2019 American Transplant Congress
Evaluation of the Safety and Tolerability of Clazakizumab® (Anti-IL-6 Monoclonal) as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (nct03380962)
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Currently, there is growing interest in development of novel immune-modulatory drugs likely to improve allo-antibody reduction in transplantation. Clazakizumab (Vitaeris Inc.) is a humanized…2019 American Transplant Congress
Quantifying Differential Infection Risks in HLA- and/or ABO- Incompatible Kidney Transplant Recipients
1Johns Hopkins, Baltimore, MD, 2New York University, New York, NY
*Purpose: Desensitization has enabled kidney transplantation across HLA-and/or ABO barriers and has conferred survival benefit to patients who lack compatible living donors (CLDKT). However, due…2019 American Transplant Congress
Successful Use of Nonantigen Specific Immunoadsorption In ABO-Incompatible Desensitization and Humoral Rejection Treatment in Kidney Transplantation
Servei de Nefrologia i Trasplantament Renal, Hospital Clínic de Barcelona, Barcelona, Spain
*Purpose: : Immunoadsorption (IA) is an apheresis procedure that has been shown to be effective in the ABO incompatible living donor kidney transplantation (ABOi LDKT)…2019 American Transplant Congress
Outcomes after Prolonged Therapeutic Plasma Exchange in Pediatric Kidney Transplant Patients with Early Recurrence of Focal Segmental Glomerular Sclerosis
*Purpose: Focal segmental glomerular sclerosis (FSGS) is the most common cause of glomerulonephritis leading to end-stage renal disease (ESRD) in pediatric patients. FSGS recurs frequently…2019 American Transplant Congress
Osmotic Demyelination Syndrome after Liver Transplantation- Etiology and Treatment Options
*Purpose: Orthotopic liver transplantation (OLT) is the only effective therapy for patients with end stage liver failure that increases long-term survival, but is not without…2019 American Transplant Congress
Is Pre-transplant Plasmapheresis For Patients With Insignificant Abo Blood Type Antibody In Abo Blood Type Incompatible Kidney Transplant Necessary? – A Japanese Single Center Study.
Urology and Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Hokkaido, Japan
*Purpose: ABO incompatible kidney donor (ABOiKT) is still precious to fill up the extremely organ donor shortages in our country. Though plasmaphresis (PP) as desensitization…2018 American Transplant Congress
Treatment Outcomes of FSGS Recurrence
Background: Recurrence of FSGS (focal segmental glomerulosclerosis) after kidney transplant occurs in 30% of adults and up to 80% of children and has impact on…2018 American Transplant Congress
Modified Protocol for ABO-Incompatible Living Donor Liver Transplantation with Rituximab and Intravenous Immunoglobulin without Plasma Exchange
Center for Liver Cancer, National Cancer Center, Il-san Donggu, Goyang, Republic of Korea.
Purpose: Since a variety of desensitization strategies including rituximab, intravenous immunoglobulin (IVIG), and plasma exchange (PE) have been introduced, the survival and outcomes of recipients…2018 American Transplant Congress
modified DFPP Can Eliminate Donor-Reactive IgG Antibody with Preserving Fibrinogen before Kidney Transplantation
BACKGROUND: Elimination of preexisting IgG antibodies against donor antigen is an important role before antibody-incompatible (i.e. ABO-incompatible and donor-specific antibody positive) kidney transplantation. Plasma exchange…2018 American Transplant Congress
How Safe is Crossing the ABO Blood Group Barrier? A Meta-Analysis to Determine the Additive Risk of ABO-Incompatible Kidney Transplantation
Nephrology and Kidney Transplantation, Erasmus Medical Center, Rotterdam, Netherlands.
Background ABO blood group-incompatible (ABOi) kidney transplantation is considered a safe procedure, with non-inferior outcomes in large cohort studies. Its contribution to living kidney transplantation…
American Transplant Congress abstracts